343
Participants
Start Date
February 6, 2012
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
pregabalin
Pregabalin capsule, 300-450mg/day, twice daily
placebo
Placebo, twice daily
Beijing Chao-Yang Hospital, Capital Medical University, Beijing
China-Japan Friendship Hospital/Rheumatology Department, Beijing
Peking Union Medical College Hospital/Rheumatology Department, Beijing
PLA. The Military General Hospital of Beijing, Beijing
Rheumatology Department, The first Affiliated Hospital of Harbin Medical University, Harbin
Rheumatology Department, The second Affiliated Hospital of Harbin Medical University, Harbin
Rheumatology and Immunology Dept., Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai
Rheumatology and Immunology Department, Shanghai Changzheng Hospital, Shanghai
Zhongshan Hospital Fudan University, Rheumatology Department, Shanghai
Anhui Province Hospital, Hefei
Department of Rheumatism And Immunity, The First Affiliated Hospital of Bengbu Medical College, Bengbu
The First Affiliated Hospital of Wenzhou Medical University/Neurology Department, Wenzhou
The Second Affiliated Hospital to Nanchang University, Nanchang
Southwest Hospital of the Third Military Medical University,PLA, Chongqing
Xiangya Hospital of Centre-south University, Changsha, Kaifu District
Department of Neurology,General Hospital of Guangzhou Military Command of PLA, Guangzhou
Guangdong General Hospital, Guangzhou
Department of Neurology,The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou
The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou
Si Chuan Huaxi Hospital/Rheumatology Department, Chengdu
The First Affiliated Hospital of Kunming Medical University/ Rheumatology and Immunology Department, Kunming
Xijing Hospital, The Fourth Military Medical University, Xi’an
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY